



Tamiko Katsumoto

Clinical Assistant Professor, Medicine - Immunology & Rheumatology

CLINICAL OFFICES

- **Immunology and Rheumatology Clinic**

900 Blake Wilbur Dr Rm W2081

2nd Fl

Stanford, CA 94305

Tel (650) 723-6961 **Fax** (650) 725-8418

Bio

BIO

Tamiko Katsumoto, MD, is a Clinical Assistant Professor in the Division of Immunology and Rheumatology at Stanford University. She earned her MD from the University of California, San Francisco. She completed her internal medicine residency and rheumatology fellowship at UCSF, including a postdoc in the immunology lab of Dr. Arthur Weiss. Dr. Katsumoto's research interests include the discovery of novel biomarkers to predict the development of immune-related adverse events in cancer patients on immune checkpoint inhibitor therapies, and optimizing the management of such complications. She is fascinated by the relationship between cancer and autoimmune diseases such as scleroderma and dermatomyositis, the paraneoplastic manifestations of various cancers, and the rheumatic complications of graft vs. host disease. She has spent time at Genentech, where she led several clinical trials in immunology. She also serves as a grant reviewer for the American College of Rheumatology Translational/Clinical Study Section and serves on the Medical and Scientific Board of the Northern California Chapter of the Arthritis Foundation.

CLINICAL FOCUS

- Rheumatology
- Immunology
- Immuno-Oncology and immune-related adverse events
- Scleroderma (Systemic Sclerosis)

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Immunology & Rheumatology

HONORS AND AWARDS

- Reviewer for Career Development Research Awards, American College of Rheumatology (2018-present)
- CDRMP Peer Reviewer, Department of Defense (2017)
- Jo Rae Wright Early Career Investigator Award, American Thoracic Society (2012)
- Laura Bechtel Junior Faculty Award, UCSF (2012)
- Rheumatology Investigator Award, American College of Rheumatology - Research and Education Foundation (2011-2013)

- Physician Scientist Development Award, American College of Rheumatology - Research and Education Foundation (2008-2011)
- Molecular Medicine Fellow, UCSF (2002-2008)
- Professionalism Award, UCSF Internal Medicine Residency Program (2005)
- Alpha Omega Alpha honor society, UCSF chapter (2002)
- Dean's Prize for Student Research, UCSF (2002)
- Research Fellowship and Support for Completion of Medical Studies, Howard Hughes Medical Institute (1999-2001)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, American College of Rheumatology (2005 - present)
- Medical and Scientific Board, Arthritis Foundation (2019 - present)
- Member, Society for Immunotherapy of Cancer (SITC) (2019 - present)

PROFESSIONAL EDUCATION

- Board Certification: Rheumatology, American Board of Internal Medicine (2008)
- Fellowship: UCSF Rheumatology Fellowship (2008) CA
- Residency: UCSF Department of Medicine (2005) CA
- Medical Education: University of California at San Francisco School of Medicine (2002) CA

Publications

PUBLICATIONS

- **Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study).** *Arthritis & rheumatology (Hoboken, N.J.)*
Cohen, S., Tuckwell, K., Katsumoto, T. R., Zhao, R., Galanter, J., Lee, C., Rae, J., Toth, B., Ramamoorthi, N., Hackney, J. A., Berman, A., Damjanov, N., Fedkov, et al
2020
- **Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study**
Cohen, S., Tuckwell, K., Kunder, R., Katsumoto, T., Zhao, R., Berman, A., Damjanov, N., Fedkov, D., Jeka, S., Genovese, M.
WILEY.2019
- **FENEBRUTINIB COMPARED TO PLACEBO AND ADALIMUMAB IN PATIENTS WITH INADEQUATE RESPONSE TO EITHER METHOTREXATE THERAPY OR PRIOR TNF THERAPY: PHASE 2 STUDY**
Cohen, S., Tuckwell, K., Katsumoto, T. R., Zhao, R., Lee, C., Berman, A., Damjanov, N., Fedkov, D., Jeka, S., Genovese, M. C.
BMJ PUBLISHING GROUP.2019: 80–81
- **Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis.** *Lupus science & medicine*
Gomez Mendez, L. M., Cascino, M. D., Katsumoto, T. R., Brakeman, P., Brunetta, P., Jayne, D., Dall'Era, M., Rovin, B., Garg, J.
2019; 6 (1): e000308
- **Absence of Pharmacokinetic Interactions Between the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate.** *The Journal of pharmacology and experimental therapeutics*
Jones, N. S., Winter, H., Katsumoto, T. R., Florero, M., Murray, E., Walker, H., Singh, N., Chinn, L.
2019
- **Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies.** *Current treatment options in oncology*
Lippner, E. A., Lewis, D. B., Robinson, W. H., Katsumoto, T. R.
2019; 20 (7): 62
- **Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis.** *Clinical journal of the American Society of Nephrology : CJASN*
Gomez Mendez, L. M., Cascino, M. D., Garg, J., Katsumoto, T. R., Brakeman, P., Dall'Era, M., Looney, R. J., Rovin, B., Dragone, L., Brunetta, P.

2018; 13 (10): 1502–9

- **Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor.** *Clinical pharmacology and therapeutics*
Herman, A. E., Chinn, L. W., Kotwal, S. G., Murray, E. R., Zhao, R., Florero, M., Lin, A., Moein, A., Wang, R., Bremer, M., Kokubu, S., Serone, A. P., Hanze, et al
2018; 103 (6): 1020–28
- **Brief Report: Whole-Exome Sequencing for Identification of Potential Causal Variants for Diffuse Cutaneous Systemic Sclerosis.** *Arthritis & rheumatology (Hoboken, N.J.)*
Mak, A. C., Tang, P. L., Cleveland, C., Smith, M. H., Kari Connolly, M., Katsumoto, T. R., Wolters, P. J., Kwok, P. Y., Criswell, L. A.
2016; 68 (9): 2257–62
- **Outcomes in systemic sclerosis-related lung disease after lung transplantation.** *Transplantation*
Sottile, P. D., Iturbe, D., Katsumoto, T. R., Connolly, M. K., Collard, H. R., Leard, L. A., Hays, S., Golden, J. A., Hoopes, C., Kukreja, J., Singer, J. P.
2013; 95 (7): 975–80
- **The phosphatase CD148 promotes airway hyperresponsiveness through SRC family kinases.** *The Journal of clinical investigation*
Katsumoto, T. R., Kudo, M., Chen, C., Sundaram, A., Callahan, E. C., Zhu, J. W., Lin, J., Rosen, C. E., Manz, B. N., Lee, J. W., Matthay, M. A., Huang, X., Sheppard, et al
2013; 123 (5): 2037–48
- **Cut to the quick.** *Journal of hospital medicine*
Su, R., Katsumoto, T. R., George, V., Gundling, K., Hollander, H.
2013; 8 (2): 110–13
- **Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.** *Respiratory medicine*
Lee, J. S., Kim, E. J., Lynch, K. L., Elicker, B., Ryerson, C. J., Katsumoto, T. R., Shum, A. K., Wolters, P. J., Cerri, S., Richeldi, L., Jones, K. D., King, T. E., Collard, et al
2013; 107 (2): 249–55
- **Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts.** *Seminars in arthritis and rheumatism*
Walker, K. M., Pope, J.
2012; 42 (1): 42–55
- **Blocking TGF β via inhibition of the α 6 β 1 Integrin: A Possible Therapy for Systemic Sclerosis Interstitial Lung Disease.** *International journal of rheumatology*
Katsumoto, T. R., Violette, S. M., Sheppard, D.
2011; 2011: 208219
- **Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'.** *Nature*
Goodridge, H. S., Reyes, C. N., Becker, C. A., Katsumoto, T. R., Ma, J., Wolf, A. J., Bose, N., Chan, A. S., Magee, A. S., Danielson, M. E., Weiss, A., Vasilakos, J. P., Underhill, et al
2011; 472 (7344): 471–75
- **Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis.** *The Journal of rheumatology*
Walker, K. M., Pope, J.
2011; 38 (7): 1326–28
- **The pathogenesis of systemic sclerosis.** *Annual review of pathology*
Katsumoto, T. R., Whitfield, M. L., Connolly, M. K.
2011; 6: 509–37
- **Structurally distinct phosphatases CD45 and CD148 both regulate B cell and macrophage immunoreceptor signaling.** *Immunity*
Zhu, J. W., Brdicka, T., Katsumoto, T. R., Lin, J., Weiss, A.
2008; 28 (2): 183–96
- **Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells.** *The Journal of experimental medicine*
Katsumoto, T. R., Duda, J., Kim, A., Wardak, Z., Dranoff, G., Clapp, D. W., Shannon, K.

2005; 201 (6): 853–58

- **Polymerized liposome assemblies: Bifunctional macromolecular selectin inhibitors mimicking physiological selectin ligands** *BIOCHEMISTRY*

Bruehl, R. E., Dasgupta, F., Katsumoto, T. R., Tan, J. H., Bertozzi, C. R., Spevak, W., Ahn, D. J., ROSEN, S. D., Nagy, J. O.

2001; 40 (20): 5964–5974

- **Ligation of L-selectin on T lymphocytes activates beta1 integrins and promotes adhesion to fibronectin.** *Journal of immunology (Baltimore, Md. : 1950)*

Giblin, P. A., Hwang, S. T., Katsumoto, T. R., Rosen, S. D.

1997; 159 (7): 3498–3507

- **L-selectin-carbohydrate interactions: Relevant modifications of the Lewis x trisaccharide** *BIOCHEMISTRY*

Sanders, W. J., Katsumoto, T. R., Bertozzi, C. R., ROSEN, S. D., Kiessling, L. L.

1996; 35 (47): 14862–14867